Tim H. Brümmendorf - Concepedia

Author

Tim H. Brümmendorf

Also Known As

Andreas Hochhaus, Brümmendorf, Tim H., Brümmendorf, Tim Henrik, Brümmendorf, Tim Henrik 1966-, Françoise Huguet, Jolanta Dengler, Karsten Spiekermann, Maximilian Ackermann, R. Büttner, Robert Meyer

589

Publications

15.3K

Citations

H-Index

129

Concepts

All Affiliations

RWTH Aachen University Universitätsklinikum Aachen University Medical Center Hamburg-Eppendorf Universität Hamburg Heidelberg University

About

Tim H. Brümmendorf is an author at RWTH Aachen University specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	75	4.6K
2	Health Sciences	17	26	1.6K
3	Engineering	2	2	114
4	Public Health	2	2	66
5	Natural Sciences	1	1	16

Tim H. Brümmendorf

201

Publications

13.4K

Citations

H-Index

Page 1

	Year	Citations
Aging of blood can be tracked by DNA methylation changes at just three CpG sites Carola I. Weidner, Qiong Lin, Carmen Koch, Genome biology	2014	926
Telomere Fluorescence Measurements in Granulocytes and T Lymphocyte Subsets Point to a High Turnover of Hematopoietic Stem Cells and Memory T Cells in Early Childhood Nathalie Rufer, Tim H. Brümmendorf, Steen Kølvraa, The Journal of Experimental Medicine Telomere Fluorescence MeasurementsDevelopmental BiologyHigh TurnoverCell DivisionNaive T Cells	1999	713
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Journal of Clinical Oncology	2017	480
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial Jörge E. Cortes, Dong‐Wook Kim, Hagop M. Kantarjian, Journal of Clinical Oncology	2012	465
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Blood	2011	457
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure H. Jean Khoury, Jörge E. Cortes, Hagop M. Kantarjian, Blood	2012	315
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 Rebekka K. Schneider, Monica Schenone, Mónica Ventura Ferreira, Nature Medicine Lymphocyte DevelopmentMolecular RegulationGeneticsBlood CellRps14 Haploinsufficiency	2016	244
Statins Enhance Migratory Capacity by Upregulation of the Telomere Repeat-Binding Factor TRF2 in Endothelial Progenitor Cells Ioakim Spyridopoulos, Judith Haendeler, Carmen Urbich, Circulation	2004	229
HER-2 amplification is highly homogenous in gastric cancer Andreas H. Marx, Lars Tharun, Johanna Muth, Human Pathology Tumor BiologyGastrointestinal OncologyMedicinePathologyGastric Cancer	2009	206

Page 1